Optimum News

Verona Pharma Appoints David Moskowitz as Vice President, Capital Markets Strategy & Investor Relations

LONDON, Jan. 07, 2020 (GLOBE NEWSWIRE) — Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces the appointment of David Moskowitz … Continue reading “Verona Pharma Appoints David Moskowitz as Vice President, Capital Markets Strategy & Investor Relations”

By Optimum

Novo Holdings REPAIR Impact Fund Invests USD 12 million in Mutabilis and IBT Vaccines and provides strategic update

‒        The Fund has now committed a total of USD 48 million to eight companies ‒        REPAIR to adjust strategic scope for 2020 ‒        Global call for investment proposals will open during summer … Continue reading “Novo Holdings REPAIR Impact Fund Invests USD 12 million in Mutabilis and IBT Vaccines and provides strategic update”

By Optimum

STORM Therapeutics’ collaborator awarded ASH–BSH Abstract Achievement Award at the 61st ASH Annual Meeting & Exposition

09 December 2019, Cambridge, UK: STORM Therapeutics, the biotechnology company focused on the discovery of small molecule therapies modulating RNA epigenetics announces today, that its collaborator Dr. Konstantinos Tzelepis, Sir … Continue reading “STORM Therapeutics’ collaborator awarded ASH–BSH Abstract Achievement Award at the 61st ASH Annual Meeting & Exposition”

By Optimum

Takeda and Enzyre to Develop Diagnostic Device Allowing Hemophilia Patients to Determine their Coagulation Status at Home

Enzyre, which is developing breakthrough ambulant diagnostic technology for coagulation testing, today announced that it has entered into a research collaboration agreement with Takeda Pharmaceutical Company Limited (Takeda) to develop … Continue reading “Takeda and Enzyre to Develop Diagnostic Device Allowing Hemophilia Patients to Determine their Coagulation Status at Home”

By Optimum

Owkin Teams up with NVIDIA and King’s College London to Deliver AI to Hospitals While Protecting Patient Data With Federated Learning

PARIS and NEW YORK, Dec. 2, 2019 /PRNewswire/ — Owkin, which is developing Federated Learning and AI technologies to advance medical research, announces it is teaming up with technology company NVIDIA and King’s College London (KCL) to … Continue reading “Owkin Teams up with NVIDIA and King’s College London to Deliver AI to Hospitals While Protecting Patient Data With Federated Learning”

By Optimum

European CNS Specialist Neuraxpharm Expands Southern European Presence with Expansion into Portugal

LANGENFELD, Germany, Nov. 28, 2019 /PRNewswire/ — Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the central nervous system (CNS), announces expansion of its operations in Southern Europe with the launch of Neuraxpharm … Continue reading “European CNS Specialist Neuraxpharm Expands Southern European Presence with Expansion into Portugal”

By Optimum

Castor Establishes Advisory Board of Industry Leaders to Maximize the Impact of its Clinical Data Platform

Industry veterans including Craig Lipset will support Castor’s vision to advance the future of clinical research Amsterdam, Netherlands and Hoboken, New Jersey:  November 18, 2019: Castor, a health-tech company that … Continue reading “Castor Establishes Advisory Board of Industry Leaders to Maximize the Impact of its Clinical Data Platform”

By Optimum

Artios Pharma, MD Anderson and ShangPharma Announce In-Licensing Agreement for DNA Damage Response Inhibitor

CAMBRIDGE, England and HOUSTON and SOUTH SAN FRANCISCO, Calif., Nov. 6, 2019 /PRNewswire/ — Artios Pharma Limited (Artios), The University of Texas MD Anderson Cancer Center (MD Anderson) and ShangPharma Innovation (ShangPharma) today announce the in-licensing by Artios of … Continue reading “Artios Pharma, MD Anderson and ShangPharma Announce In-Licensing Agreement for DNA Damage Response Inhibitor”

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH